Iconovo Gets Positive FDA Verdict On Ellipta Substitution
ICOpre Inhaler Endorsed By Agency; Earliest Potential EU Launch Date Remains 2027
Iconovo’s efforts in bringing its Breo Ellipta rival to the market continue, with positive news received from the FDA on the substitutability of the firm’s ICOpre proprietary inhaler. The firm is now seeking a partner to take the product to the next stage.
